📰 Human Use News
Page 106 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
November 4, 2022
Investegate announcements from AstraZeneca PLC, Beyfortus (nirsevimab) approved in EU
November 3, 2022
EMA accepts application for RSV older adult vaccine, the first potential vaccine for these patients with lower respiratory tract disease.
November 3, 2022
Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organization in key strategic therapeutic areas: immunology and oncologyJyseleca 2022
November 3, 2022
Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 11% Third quarter 2022...
November 3, 2022
BeiGene has secured marketing authorisation from the European Commission (EC) for Brukinsa (zanubrutinib) to treat marginal zone lymphoma (MZL)
November 3, 2022
Investegate announcements from Galapagos NV, Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
November 2, 2022
BRUKINSA is the first and only Bruton's Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma approved in the European Union BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology
November 2, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
October 31, 2022
Investegate announcements from Santhera Pharmaceuticals Holdi, European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
October 31, 2022
Pratteln, Switzerland, October 31, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone